Semiconducting polymer nano-radiopharmaceutical for combined radio-photothermal therapy of pancreatic tumor

Xiumin Shi1,2†, Qing Li1†, Chuan Zhang1†, Hailong Pei1, Guanglin Wang1, Hui Zhou1, Longfei Fan1, Kai Yang1, Bo Jiang3*, Feng Wang2* and Ran Zhu1*

Abstract

**Background:** Pancreatic ductal adenocarcinoma (PDAC) is a devastatingly malignant tumor with a high mortality. However, current strategies to treat PDAC generally have low efficacy and high side-effects, therefore, effective treatment against PDAC remains an urgent need.

**Results:** We report a semiconducting polymer nano-radiopharmaceutical with intrinsic photothermal capability and labeling with therapeutic radioisotope $^{177}$Lu ($^{177}$Lu-SPN-GIP) for combined radio- and photothermal therapy of pancreatic tumor. $^{177}$Lu-SPN-GIP endowed good stability at physiological conditions, high cell uptake, and long retention time in tumor site. By virtue of combined radiotherapy (RT) and photothermal therapy (PTT), $^{177}$Lu-SPN-GIP exhibited enhanced therapeutic capability to kill cancer cells and xenograft tumor in living mice compared with RT or PTT alone. More importantly, $^{177}$Lu-SPN-GIP could suppress the growth of the tumor stem cells and reverse epithelial mesenchymal transition (EMT), which may greatly reduce the occurrence of metastasis.

**Conclusion:** Such strategy we developed could improve therapeutic outcomes over traditional RT as it is able to ablate tumor with relatively lower doses of radiopharmaceuticals to reduce its side effects.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Pancreatic ductal adenocarcinoma (PDAC), as the most common type of pancreatic tumors, has poor prognosis and high mortality with 5-year overall survival rate less than 10% [1]. Such low survival rate is commonly caused by rapid tumor progression, easy metastasis and the absence of early symptom of PDAC [2–4]. Resultantly, the majority of patients with PDAC are diagnosed at advanced or metastatic stage and thus are refractory through surgical resection [5]. At such advanced stage, other therapeutic strategies such as chemotherapy have limited efficacy due to its high chemoresistance [6]. Therefore, the high aggressiveness, metastasis and chemoresistance of PDAC urge researchers to exploit new and more effective therapeutic strategies to improve the survival of PDAC patients.

Combined therapy provides new opportunities for effective cancer treatment by utilizing the complementary advantages of different therapeutic methods [7, 8]. For instance, radiotherapy (RT), one of the most effective treatment strategies, has been extensively used in clinical cancer treatment [9–12]. However, some cancers including pancreatic cancer are relatively resistant to RT due to their inherent hypoxic microenvironment within tumor [13]. To overcome this limitation, the combination of RT with other treatment modalities is considered as a promising method to improve therapeutic efficiency.

In recent years, various therapeutic modalities such as photothermal therapy (PTT), photodynamic therapy, and immunotherapy have been developed to combine with RT for improving the tumor cell killing effects [14–16]. Among these therapeutic modalities, PTT, which capitalizes on photothermal effect that converts absorbed near-infrared light energy into heat [17–19], has emerged as a potential treatment for cancers due to its high specificity, minimal wound and low side-effects [20]. It has been demonstrated that appropriate hyperthermia not only has the ability to kill the tumor cells that are less sensitive to RT but also can accelerate intratumoral blood flow, which leads to the improvement of oxygen level in tumor and thus relieves the resistance of tumor cells to RT [21, 22]. Therefore, by virtue of the merits, the combination of PTT with RT endows enhanced therapeutic effect against tumors. To date, a series of nanoagents integrating RT with PTT have been developed but have not been explored for PDAC treatment [23, 24]. Besides, most of these reported nanoagents are based on inorganic materials, leading to potential toxicity and impeding their clinical application [25].

Semiconducting polymer nanoparticles (SPNs) composed of completely organic compounds have been emerged as photothermal agents for tumor therapy.
Compared with other inorganic nanomaterials such as gold nanorods and carbon nanotubes, SPNs possess unique characteristics such as better biocompatibility, higher NIR absorption and photothermal conversion efficiency, feasibility and controllability [30–34]. In particular, SPNs not only allow for convenient chemical engineering of backbones and side chains for on-demand functionalization, but also are conducive to nanoengineering to achieve size or morphology controllability [35]. To date, the utilization of SPNs for PTT has been fully explored, but combined therapy are rarely reported [10, 36, 37].

In this study, we develop a 177Lu-labeled semiconducting polymer nano-radiopharmaceutical with glucose-dependent insulino tropic polypeptide (GIP) as tumor targeting group (177Lu-SPN-GIP) for combined RT and PTT of PDAC (Scheme 1a). 177Lu-SPN-GIP was designed to comprise radioactive 177Lu as a tracer for SPECT/CT imaging and also as a killer for tumor with a SPN to serve for PTT treatment of cancer. Such combination of different treatment techniques could complement each other, offering accurate monitoring and comprehensive therapeutic effects relative to PTT or RT alone. This is a simple yet effective approach to fabricate SPNs-based multifunctional theranostic nanoplatform for treatment of pancreatic tumor.

**Experimental section**

**Preparation of 177Lu-SPN-GIP**

177LuCl3·HCl solution (35 µL, 18.5–37MBq) was dissolved in 10 µL of 0.25 M sodium acetate (NaOAc). Then SPN-GIP solution (100 µg mL−1, 0.05 mL) was added into the above solution and then stirred at room temperature for 30 min. The crude product was centrifuged with 100 K ultrafiltration tube at 3000 r min−1 for 5 min three times. The radiochemical purity of 177Lu-SPN-GIP was measured by paper chromatography (mobile phase: pure water).

**PTT and RT of cells**

CFPAC-1 cells were seeded in 96-well plates (5 × 10^3 cells well−1) and cultured at 37 °C for 24 h. Then different concentrations of 177LuCl3 or 177Lu-SPN-GIP (0.37, 3.70, 7.40, 11.10, 14.80 and 18.5 MBq mL−1) were added and incubated with cells for 24 h. After incubation, cells were washed and fresh medium was added to each well, and the cells were incubated for another 96 h. Cell viability was measured using the CCK-8 assay. For cell viability of different dose of 177Lu-SPN-GIP combined with PTT, after 24-h incubation of 177Lu-SPN-GIP (0.37, 3.70, 7.40, 11.10, 14.80 and 18.5 MBq mL−1) mixing with 50 μg mL−1 SPN-GIP, cells were irradiated with 808 nm laser (1 W cm−2, 5 min), then incubation of fresh medium for another 24 h before measured using the CCK-8 assay.

For live-dead cell imaging experiments, cells were firstly incubation with normal medium, 50 µg mL−1 of SPN-GIP, 177LuCl3 (1.11 MBq), and 177Lu-SPN-GIP (1.11 MBq) for 24 h and then with or without irradiated by an 808 nm laser at the power density of 1 W cm−2 for 5 min. Afterwards, cells were co-stained with a live/dead cell staining kit to monitor live and dead cells. The double staining kit contains acetoxymethyl ester of calcein to stain viable cells with green fluorescence, and propidium iodide to stain dead cells with red fluorescence.

**Therapeutic effect**

Animal experiments were performed using 6–8 weeks old male BALB/c nude mice (Cavens, Changzhou, China). To create the pancreas cancer model, a single-cell suspension of 2 × 10^6 CFPAC-1 cells in 75 μL of IMDM without serum was injected into the right leg of BALB/c nude mice. On the tenth day after subcutaneous inoculation, mice with tumor diameter at about 4–5 mm were selected for further studies. All animal experiments were conducted according to the animal research guidelines provided by the Animal Care and Use Committee at the Soochow University. Six groups of mice were received 177LuCl3 (1.11 MBq), 177Lu-SPN-GIP (1.11 MBq), 177Lu-SPN-GIP (1.11 MBq) with PTT and saline (n = 5), respectively. The excitation laser (808 nm) was generated from cnilaser YZ808KD1000-34F (1 W cm−2) and the temperature of tumor was controlled around 45 °C by the distance between the cnilaser and the tumor surface which was recorded by FLIR camera.

**SPECT/CT imaging**

CFPAC-1 bearing mice (at t = 10-day after subcutaneous inoculation) were intratumorally injected with 1.11 ± 0.11 MBq of 177Lu-SPN-GIP, or 177LuCl3. SPECT/CT scans were conducted by a small animal SPECT/CT imaging system (U-SPECT/CT, MILabs, Netherlands) at different time points (0.5, 24, 48 and 96 h).

**Results and discussions**

**Synthesis and characterization of SPN-GIP and 177Lu-SPN-GIP**

Scheme 1a presents the synthetic procedures of SPN-GIP and 177Lu-SPN-GIP. SPN-GIP was prepared using a nanoprecipitation method. A semiconducting polymer poly[2,1,3-benzothiadiazole-4,7-diyl][4,4-bis(2-ethylhexyl)-4H-cyclopenta[2,1-b:3,4-b’ dithiophene-2,6-diyl]] (PCPDTBT) was encapsulated with functionalized amphiphilic polymer (GIP-PEG12 DSPE and DOTA-PEG12-DSPE) to obtain water-soluble
Further radiolabeling of SPN-GIP was performed through chelating $^{177}$Lu with DOTA on its surface to get the final radioactive nanoagent $^{177}$Lu-SPN-GIP. Transmission electron microscopy (TEM) revealed the spherical morphology of SPN-GIP with an average size of 207.70 nm (Fig. 1a). The hydrodynamic diameter of SPN-GIP in PBS was measured to be 187.8±2.26 nm (Fig. 1a). SPN-GIP had an absorption in the NIR region with a maximum peak at 680 nm, which was originated from PCPDTBT (Fig. 1b). SPN-GIP had no obvious change in absorption intensity after 808 nm laser irradiation, suggesting its excellent photostability for further

**Scheme 1** a Synthesis and characterization of SPN-GIP and $^{177}$Lu-SPN-GIP. b Representative schematic illustration of the fabrication of SPNs and combined RT and PTT.
The radiolabeling efficiency of $^{177}$Lu-SPN-GIP was $86.36 \pm 6.12\%$ with a high radiochemical purity of $97.48 \pm 1.90\%$. After a 48-h incubation, the radiochemical purity of $^{177}$Lu-SPN-GIP remained to be $89.78 \pm 0.75\%$ in saline and $84.22 \pm 2.60\%$ in FBS (Fig. 1c), indicating its suitable stability for in vivo study. The photothermal performance of SPN-GIP at various concentrations (0, 12.5, 25, and 50 $\mu$g mL$^{-1}$) was investigated with an 808 nm laser at 0.5 W cm$^{-2}$, which was recorded by an infrared thermal mapping apparatus (Additional file 1: Fig. S1). Under continuous laser irradiation at 808 nm, the temperature of SPN-GIP solutions gradually increased with increasing its concentrations. The maximum temperature increment of SPN-GIP at 12.5, 25, and 50 $\mu$g mL$^{-1}$ after laser irradiation for 270 s reached about 8.5, 16.8, and 27.1 °C, respectively (Fig. 1d). In contrast, the temperature increment of PBS solution was only 0.3 °C with the same laser irradiation density and time, indicating the capability of SPN-GIP for PTT. Remarkably, the photothermal conversion efficiency ($\eta$) reached approximately 42.84%, [25, 38], which was comparable to the previously reported photothermal agents (Additional file 1: Table S1). After three cycles of heating–cooling manipulation, no reduction of maximum temperature at each cycle was observed, indicating the perfect photothermal stability of SPN-GIP (Fig. 1e, f).

In vitro RT and PTT capability of SPN-GIP and $^{177}$Lu-SPN-GIP

Before investigating the RT and PTT performance, cell biocompatibility of SPN-GIP towards CFPAC-1 cells was firstly tested using cell counting kit-8 (CCK8) assay. As shown in Fig. 2a, SPN-GIP exhibited no appreciable toxicity to cells even at a high concentration of 50 $\mu$g mL$^{-1}$, showing its great biocompatibility. However, after labeling with $^{177}$Lu, $^{177}$Lu-SPN-GIP showed dose-dependent decrease in cell viability (Fig. 2b). In contrast, free $^{177}$LuCl$_3$ showed a significant decrease in cancer cell killing ability, which probably because the nanoparticle is a better carrier in favor of the cell uptake of $^{177}$Lu and thereafter facilitates RT within cells (Fig. 2b, Additional file 1: Fig. S2a, b). Besides, if the incubation time was extended from 24 to 96 h after replacing the medium containing $^{177}$Lu-SPN-GIP with fresh medium, the cell viability could be apparently decreased, indicating RT necessitates enough time to exert the killing effect. Then, a combination of RT and PTT was further investigated. After co-incubation with SPN-GIP (50 $\mu$g mL$^{-1}$) and $^{177}$Lu-SPN-GIP at different radioactive dosage ranging from 0 to 11.1 MBq mL$^{-1}$ for 24 h, CFPAC-1 cells were irradiated by an 808 nm laser (1 W cm$^{-2}$, 5 min) and then incubated for another 24 h. After convergence with
PTT, cell viability could be inhibited more effectively relative to RT alone. Specifically, after treatment with PTT along with RT at the dosage of 11.1 MBq mL\(^{-1}\) (1.11 MBq, 0.1 mL), cell viability could be decreased to 4.33 ± 3.03%, which was 7.74-fold and 18.58-fold lower than those of PTT and RT alone, respectively (Fig. 2b). Such combination of RT and PTT was demonstrated to possess outstanding effect on destructing cancer cells, which was further validated by fluorescence imaging using calcine AM and propidium iodide (PI) to stain cells after different therapeutic treatments (Fig. 2c). Therefore, the combined RT and PTT offers remarkably enhanced killing effect on cancer cells relative to RT or PTT alone.

**In vivo therapeutic effect of combined RT and PTT**

As β-emitting radiopharmaceuticals for molecular RT, \(^{177}\)Lu is routinely used to treat patients suffering from tumors with somatostatin receptor overexpression in Europe, which invariably consists of 2 or 4 intravenous administrations of \(^{177}\)Lu-DOTATATE at a high dosage (7.4 GBq) [39, 40]. Such strategy can significantly improve progression-free survival, but it needs several injections due to the fast efflux-induced short retention of radiopharmaceuticals within tumor. In this study, after intratumoral injection of \(^{177}\)Lu-SPN-GIP, a strong radioactive signal was observed in tumor and the signal kept unchanged even at \(t = 4\)-day post-injection, indicating \(^{177}\)Lu-SPN-GIP had an excellent accumulation and
retention effect in tumor region. By contrast, $^{177}\text{LuCl}_3$-treated group showed a diffused radioactive signal in the whole body within 1-day post-injection and nearly all $^{177}\text{LuCl}_3$ was excreted from the body at $t=2$-day post-injection (Fig. 3a), further validating the SPNs as a perfect nanocarrier to favor the accumulation and retention of radiopharmaceuticals for therapy.

As it well known, heat causes irreversible damage to cancer cell membranes and initiates protein denaturation [16, 41]. In order to avoid unnecessary thermal effect to proximal normal tissues, the temperature of PTT was held around 45 °C [42, 43]. The temperature changes of the tumor area were recorded by IR thermal mapping apparatus. According to the IR thermographic images (Additional file 1: Fig. S3), the temperature at tumor area rapidly reached 45 °C after treatment with SPN-GIP under the laser irradiation for 30 s. The temperature of the tumor without treatment with SPNs presented subtle changes under the same irradiation conditions for 5 min, thereby demonstrating that the high in vivo photothermal effect of SPN-GIP.

Therapeutic efficacy of combined RT and PTT was then evaluated by monitoring the tumor growth after various treatments including saline, SPN-GIP, $^{177}\text{LuCl}_3$, SPN-GIP with laser, $^{177}\text{Lu}$-SPN-GIP, and $^{177}\text{Lu}$-SPN-GIP with PTT (Fig. 3b–d). As shown in Fig. 3b, tumor volume in the saline-treated group grew over time. Though the tumor size of $^{177}\text{LuCl}_3$-treated group at $t=7$-day post-injection was slightly suppressed relative to those at $t=4$-day post-injection probably due to the inherent killing effect of β-rays emitted by $^{177}\text{Lu}$, but there was no significant difference in comparison to the saline group post-treatment at day 21 ($P=0.2077$). Compared with $^{177}\text{LuCl}_3$-treated group, $^{177}\text{Lu}$-SPN-GIP showed obviously improved therapeutic capability in suppressing the tumor growth, attributing to increased tumor accumulation and retention effect of $^{177}\text{Lu}$-SPN-GIP relative to free $^{177}\text{LuCl}_3$. Owing to ideal photothermal effect of

![Fig. 3](image-url)
SPN-GIP, SPN-GIP with PTT-treated group apparently inhibited the tumor growth after PTT while no therapeutic effect was observed for the group without laser irradiation (SPN-GIP group). Unfortunately, due to the low efficiency and incomplete killing of cancer cells, tumor recurrence was observed in both RT and PTT groups. By contrast, combined RT and PTT-treated group successfully inhibited the tumor growth within 21-day observation window. On the 21th day after treatment, mice of different groups were sacrificed and the residual tumor tissues were collected (Fig. 3c). Combine RT and PTT group presented the complete elimination of tumors while residual tumors were still observed in other groups receiving RT and PTT alone (Fig. 3c).

Tumors from various treatment groups were also collected for H&E staining (Fig. 3d). A mass of tumor cells was found almost in all the field of views in the control groups (including saline, SPN-GIP only, and 177LuCl3 group). As a comparison, the number of tumor cells was greatly reduced but a tiny of tumor cells was still observed in the RT and PTT alone-treated groups, indicating the incomplete killing effect of these groups. By contrast, no tumor cells were residual in combined PTT and RT group, which was in agreement with in vivo therapeutic result shown in Fig. 3b.

Besides, for mice in all groups, no significant weight loss was observed during 21-day observation period (Additional file 1: Fig. S4), and no noticeable histopathological abnormalities were found in heart, liver, spleen, lung, kidney, pancreas and intestine (Additional file 1: Fig. S5). In addition, serum biochemistry assay and blood glucose (GLU) test were also carried out for mice in all groups at t = 21-day post-treatment. There was no significant difference in GLU level between all treatment groups, suggesting there was no islet injury in all groups (Additional file 1: Fig. S5a). The liver (aspartate transaminase, AST and alanine transaminase, ALT) and kidney function markers (creatinine, CRE and blood urea nitrogen, URE) were measured and no significant difference was observed between treated groups and saline-treated group (Additional file 1: Fig. S5b, c). Therefore, these results verified the high therapeutic efficacy of synergistic PTT and RT with negligible risks towards the living organisms.

### Mechanistic study on therapeutic effect

Epithelial-mesenchymal transition (EMT) is an important process to transform epithelial cells into mesenchymal cells, which is involved in tumorigenesis, invasion and metastasis [44, 45]. In the process of EMT, the epithelial marker E-cadherin is downregulated, while the mesenchymal markers N-cadherin, fibronectin, and vimentin are upregulated significantly [46]. By comparing with the expression of E-cadherin, N-cadherin, vimentin, and fibronectin in pancreatic tumor tissue with that in normal pancreas, EMT process was verified to occur in PDAC (Additional file 1: Fig. S6). Therefore, we utilized the method to evaluate the EMT process after various therapeutic treatments. Remarkably, the expression of the epithelial marker E-cadherin was upregulated meanwhile mesenchymal markers such as N-cadherin, vimentin, and fibronectin were downregulated in RT and combined RT/PTT-treated groups (Fig. 4). Such phenomenon verified that the EMT process was effectively reversed and thus resulted in reduced risk of tumor metastasis and invasion in both treatment groups [46]. Despite endowing the fast ablation of tumor, PTT-treated group showed similar expression of mesenchymal markers to saline-treated group, implying its inability to reverse EMT process. The imbalanced of upregulated epithelial E-cadherin in PTT-treated group was probably due to high temperature-induced the lysosome inactivation of the inhibition pathway or degradative pathway of E-cadherin [47]. Thus, the combination of PTT and RT not only facilitates efficient reversion of EMT process derived from RT but also enables fast tumor ablation contributed from PTT.

Histological changes after different treatment were further analyzed (Fig. 5). As shown in Fig. 5, after treatment with PTT, RT, or the combination of PTT and RT, CD31 was changed from strong positive to weakly positive as compared with saline-treated group, indicating the successful anti-angiogenic effect of all therapeutic groups [48]. As a characteristic marker of tumor proliferation and aggressiveness, Ki67 was apparently decreased in the RT and RT/PTT-combined treatment group, indicating that the proliferation ability of tumor cells was greatly reduced [49]. However, there was no observable changes in the expression of Ki67 between PTT-treated group and saline-treated group although the tumors were rapidly ablated by elevated temperature. This was consistent with slow increase of tumor volume post-PPT treatment alone during observation window in Fig. 3. Such proliferating tendency post PTT treatment was possibly induced by its low efficiency to suppress the growth of the tumor margin and thus cause tumor proliferation and aggressiveness [14]. Thus, H&E staining was utilized to further investigate the tumor proliferation at its margin. As an expectation, an extensive generation of new capillaries was presented in the PTT-treated group relative to other groups. Such resulted abundance of capillaries could become a microenvironment conducive to tumor growth and spread. Besides, CD44 related to cancer stem cells (CSC) was also analyzed [46]. CSC is an important factor to predict the difficulty of tumor curability. Some studies showed that CSCs are closely related to EMT, resulted in expression of stem cell markers [45].
Compared with saline-treated group, the expression of CD44 was still observable in PTT-treated group, suggesting the existence of CSC and thereby implying a potential for recurrence. By contrast, the expression of CD44 decreased significantly in RT-treated and RT/PTT-combined-treated groups, validating the effective killing of CSC via 177Lu-induced damage of DNA double strands, which was also confirmed by positive immunofluorescence of γ-H2AX in cells and tissues of both groups (Additional file 1: Figure S7) [40]. In addition, CD90 expression was found increasing remarkably in the RT and RT/PTT-combined-treated groups, indicating the effective tumor-suppression while PTT-treated group showed its inferiority in the expression level [52]. All the data proved that combined PTT with RT not only achieved rapid tumor ablation derived from PTT, but also reversed EMT process and reduced the risk of invasiveness attributing to RT, providing a new attempt for effective tumor treatment.

**Conclusions and future perspectives**

In summary, we developed the nano-radiopharmaceutical (177Lu-SPN-GIP) as a therapeutic agent for the combination of RT and PTT to treat pancreatic tumor. 177Lu-SPN-GIP was prepared by functionalizing SPNs with GIP and DOTA for targeting GIPR-overexpressing pancreatic tumors and chelating radionuclide 177Lu, respectively. The obtained 177Lu-SPN-GIP showed great stability in saline and FBS within 48 h. Comparing with free 177Lu, 177Lu-SPN-GIP exhibited significantly increased cellular uptake and thus improved in vitro RT efficacy. Taking advantages of the gamma-ray emitted from 177Lu, SPECT/CT imaging confirmed that 177Lu-SPN-GIP showed long-term retention in tumor. By virtue of the outstanding ability of tumor ablation of SPN and radiopharmaceutical function of 177Lu, in vivo combined PTT and RT based on 177Lu-SPN-GIP achieved a remarkable enhanced therapeutic effect of pancreatic tumor. Moreover, no noticeable toxicity or side effect was observed for 177Lu-SPN-GIP at the tested dose.
within 21 days. In this study, $^{177}$Lu-SPN-GIP was able to implement PTT and RT simultaneously to achieve synergistic therapy against cancer. Such strategy could improve therapeutic outcomes over traditional RT as it is able to ablate tumor with relatively lower doses of radiopharmaceuticals to reduce its side effects. Though remarkable therapeutic effects have been obtained, the underlying mechanisms and interactions of pathological environment respond to combined therapy need to be further explored, which is meaningful to guide the exploration and advances of more effective therapeutic strategies against tumors.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12951-021-01083-0.

Additional file 1: Fig. S1. IR thermal images of different concentration of SPN-GIP (0, 12.5, 25, and 50 μg mL$^{-1}$) in the EP tube by 808 nm laser at different time point. Fig. S2. Cell culture. (a): Cells uptake of $^{177}$LuCl$_3$ and $^{177}$Lu-SPN-GIP at different time points (1, 2, 4 and 8 h). (b): Cell viability at different dose of $^{177}$Lu-SPN-GIP after 24-h incubation then changed to fresh medium for another 24, 48, 72, and 96 h. (c): Confocal imagines of CFPAC-1 cells uptake SPN-GIP at different time points (pre as control, 1, 2, 4, and 8 h). Fig. S3. IR thermal images of mice with intratumor injected at 3, 30, 60, 180, and 300 s under irradiation at the tumor region by 808nm laser at 1 W cm$^{-2}$. Fig. S4. The body weight of mice in the six treatment groups. Fig. S5. The side effect analysis data of different groups of treatment mice. (a) The blood levels of GLU from treated and saline control mice (P = 0.6141). (b) AST and ALT levels in the blood (P = 0.2252 for AST, P = 0.3394 for ALT). (c) CRE and URE levels in the blood (P = 0.5635 for CRE, P = 0.2176 for URE). (d) Hematoxylin and eosin (H&E)-stained slices of heart, liver, spleen, lung, kidney, pancreas, and intestines tissues of mice after PTT, RT, and saline treatments (at day-21 after intratumor). Scale bar: 50 μm. Fig. S6. Immunohistochemistry of EMT markers expression in normal pancreas and pancreatic cancer. Scale bar: 50 μm. Fig. S7. (a) Confocal imaging of CFPAC-1 cells after treatment with $^{177}$Lu-SPN-GIP with or without laser followed by staining with γH2AX. (b) Immunofluorescence imaging of tumor sections (10 μm) after staining with γH2AX.

Table S1. Summary of optical contrast agents for PTT agents ($\Delta T$ = temperature increase; η = photothermal conversion efficiency).

Acknowledgements

We also would like to thank the members in the Zhu Lab at Soochow University and the members in the Wang Lab in Nanjing First Hospital, Nanjing Medical University.

Authors’ contributions

The manuscript was written through contributions of all authors. XS, QL, and CZ contributed equally. All authors read and approved the final manuscript.

Funding

This work was supported by the National Key Research Program of China (2018YFA0208800), National Natural Science Foundation of China (22076132, 21976128), the Natural Science Foundation of Jiangsu Province (BK20200100, BK20190830), Suzhou Administration of Science & Technology (SYS2020082), and the Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University (GZK1201806).
Availability of data and materials
All data related to the manuscript are available in the manuscript and supporting information.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 22 August 2021 Accepted: 11 October 2021
Published online: 24 October 2021

References
1. Salvador-Barbero B, Álvarez-Fernández M, Zapatero-Solana E, El Bakkali A, Menéndez MDC, López-Casas PP, et al. CDK4/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell. 2020;37:340–53.
2. Mukhopadhyay S, Goswami D, Adesesahia PP, Burgan W, Yi M, Guerin TM, et al. Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers. Cancer Res. 2020;80:1630–43.
3. Badgley MA, Kremer DM, Carlo Maurer H, DelGiorno KE, LeePurohit HJV, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:89–95.
4. Hidalgo M, Cascinu S, Kremer DM, Carlo Maurer H, DelGiorno KE, LeePurohit HJV, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8–18.
5. Karasinska JM, Topham DJ, Kalloger SE, Jiang GH, Denroche RE, Culibrk L, et al. Altered gene expression along the glycolysis–cholesterol synthesis axis is associated with outcome in pancreatic cancer. Clin Cancer Res. 2020;26:133–46.
6. O’Reilly EM, Oh DY, Dhan I, Renouf DJ, Lee MA, Sun W, et al. Duvelumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1431–8.
7. Ng CW, Li J, Pu K. Recent progresses in phototherapy-sensitized cancer immunotherapy. Adv Funct Mater. 2018;28:1–20.
8. Li D, Dai K, Li J, Shiy, Zhang Z, Liu T, et al. A Boron-10 nitride nanosheet for combinational boron neutron capture therapy and chemotherapy of tumor. Biomaterials. 2021;268:120587.
9. Aghelvani S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radiouclides emitting α-particles or Auger electrons. Adv Drug Deliv Rev. 2017;109:102–18.
10. Ferreira CA, Ni D, Rosenkrans ZT, Cai W. Radionucleotide-activated nanoparticles and their biomedical applications. Angew Chem Int Ed. 2019;58:13232–52.
11. Ferreira CA, Goel S, Ehlerting EB, Rosenkrans ZT, Jiang D, Sun T, et al. Ultrasmall porous silica nanoparticles with enhanced pharmacokinetics for cancer theranostics. Nano Lett. 2021;21:4692–9.
12. Chen M, Guo Z, Chen Q, Wei J, Li J, Shi C, et al. Pd nanosheets with their surface coordinated by radioactive iodide as a high-performance theranostic nanocagent for orthotopic hepatocellular carcinoma imaging and cancer therapy. Chem Soc Rev. 2018;49:4268–74.
13. Ferreira CA, Ehlerting EB, Rosenkrans ZT, Jiang D, Sun T, Alucio-Sarduy E, et al. 99mTc-labeled monoclonal antibody targeting tissue factor for pancreatic cancer theranostics. Mol Pharm. 2020;17:1697–705.
14. Peng J, Xioq Y, Liq W, Yangq T, Lan J, Xia J, et al. Photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy. Adv Sci. 2018;5:1700891.
15. Yang J, Hou M, Sun W, Wu Q, Xu J, Xiong L, et al. Sequential PDT and PTT using dual-modal single-walled carbon nanohorns synergistically promote systemic immune responses against tumor metastasis and relapse. Adv Sci. 2020;7:2001088.
16. Chen J, Ning C, Zhou Z, Yu P, Zhu Y, Tan G, et al. Nanomaterials as photothermal therapeutic agents. Prog Mater Sci. 2019;99:1–26.
17. Lan G, Ni K, Lin W. Nanoscale metal–organic frameworks for phototherapeutic cancer. Coord Chem Rev. 2019;379:65–81.
18. Chen H, Zhang J, Chang K, Men X, Fang X, Zhou L, et al. Highly absorbing multispectral near-infrared polymer nanoparticles from one conjugated backbone for photoacoustic imaging and photothermal therapy. Biomaterials. 2017;144:42–52.
19. Cheng P, Pu K. Activatable phototheranostic materials for imaging–guided cancer therapy. ACS Appl Mater Interfaces. 2020;12:5286–99.
20. Chang X, Zhang M, Wang C, Zhang J, Wu H, Yang S. Graphene oxide/BaHoF5/PEG nanocomposite for dual-modal imaging and heat shock protein inhibitor-sensitized tumor photothermal therapy. Carbon. 2020;158:372–85.
21. Elming PB, Sorrenti BS, Oei AL, Franken NA, Crezee J, Overgaard J, et al. Hyperthermia: the optimal treatment to overcome radiation resistant hypoxia. Cancers. 2019;11:1–20.
22. Horsman MR, Vaupel P. Pathophysiological basis for the formation of the tumor microenvironment. Front Oncol. 2016;6:666.
23. Qian R, Maiti D, Zhong J, Xiong S, Zhou H, Zhu R, et al. Multifunctional nanographene based nanocomposites for multimodal imaging guided combined radiolabeling and radiotherapy. J Mater Chem B. 2019;7:14955–62.
24. Mendoza-Nava H, Ferro-Flores G, De María RF, Ocampo-Garcia B, Santos-Cuevas C, Azorin-Vega E, et al. Fluorescent, plasmonic, and radiotherapeutic properties of the 106-Lu-dendrimer-AuNP-folate-bombesin nanoprobe located inside cancer cells. Mol Imaging. 2017;16:1536012117704768.
25. Chen H, Fang X, Jin Y, Hu Y, Xin M, Men X, et al. Semiconducting polymer nanocavities: porogen synthesis, tunable host-guest interactions, and enhanced drug/siRNA delivery. Small. 2018;14:1800239.
26. Miao Q, Pu K. Organic semiconducting agents for deep-tissue molecular imaging: second near-infrared fluorescence, self-luminescence, and photoacoustics. Adv Mater. 2018;30: e1801778.
27. Xie C, Zhen X, Lei Q, Ni R, Pu K. Self-assembly of semiconducting polymer amphiphiles for in vivo photoacoustic imaging. Adv Funct Mater. 2017;27:1605397.
28. Hu X, Chen Z, Jin AJ, Yang Z, Gan D, Wu A, et al. Rational design of all-organic nanoplatform for highly efficient MR/NIR-II imaging-guided cancer phototheranostics. Small. 2021;17:2007566.
29. Chen X, Sun B, Jiang X, Yuan Z, Chen S, Sun P, et al. Double-conjugated acceptor polymer nanorods for photothermal therapy. Biomaterials. 2019;170:109154.
30. Yang Z, Li L, Jin A, Huang W, Chen X, Rational design of semiconducting polymer brushes as cancer theranostics. Mater Horiz. 2020;7:1474–94.
31. Shi Y, Fu Q, Li J, Liu H, Zhang Z, Liu T, et al. Covalent organic polymer as a carbamide carrier for imaging-facilitated boron neutron capture therapy. ACS Appl Mater Interfaces. 2020;12:55564–73.
32. Huang H, Mao L, Li Z, Liu Y, Fan S, Jin Y, et al. Multifunctional poly(methyl-silver coated layered double hydroxides embedded into a biodegradable polymer matrix for enhanced antibacterial and gas barrier properties. J Bioreos Bioprod. 2019;4:231–41.
33. Feng G, Zhang QG, Ding D. Design of superior phototheranostic agents guided by Jablonski diagrams. Chem Soc Rev. 2020;49:8179–234.
34. Feng L, Zhu C, Yuan H, Liu L, Lv F, Wang S. Conjugated polymer nanoparticles: preparation, properties, functionalization and biological applications. Chem Soc Rev. 2017;46:6260–33.
35. Chen P, Ma Y, Zheng Z, Wu C, Yang W, Liang G. Facile synthesis of conjugated polymers for photothermal therapy. Nat Commun. 2019;10:1–10.
36. Jiang D, Rosenkrans ZT, Ni D, Lin J, Huang P, Cai W. Nanomedicines for renal management: from imaging to treatment. Acc Chem Res. 2020;53:1869–80.
37. Roper DK, Ahn W, Hoepfner M. Microscale heat transfer transduced by surface plasmon resonant gold nanoparticles. J Phys Chem C Nanomater Interfaces. 2007;11:3636–41.
39. Kunikowska J, Zemczak A, Kołodziej M, Gut P, Łoń D, Pawlak D, et al. Tandem peptide receptor radionuclide therapy using ⁹⁰Y/¹⁷⁷Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging. 2020;47:922–33.
40. O'Neill E, Kersemans V, Allen PD, Terry SYA, Torres JB, Mosley M, et al. Imaging DNA damage repair in vivo after ¹⁷⁷Lu-DOTATATE therapy. J Nucl Med. 2020;61:743–50.
41. Melamed JR, Edelstein RS, Day ES. Eliciting the fundamental mechanisms of cell death triggered by photothermal therapy. ACS Nano. 2015;9(6):1235–45.
42. Yang Y, Zhu W, Dong Z, Chao Y, Xu L, Chen M, et al. 1D Coordination polymer nanofibers for low-temperature photothermal therapy. Adv Mater. 2017;29:1703588.
43. Gao G, Sun X, Liang G. Nanoagent-promoted mild-temperature photothermal therapy for cancer treatment. Adv Funct Mater. 2021;31:2100738.
44. Hu W, Pei H, Sun F, Li P, Nie J, Li B, et al. Epithelial-mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib. J Radiat Res. 2018;59:583–7.
45. Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation and tumorigenesis. J Cell Physiol. 2017;232:3261–72.
46. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.
47. Palacios F, Tusher JS, Fujita Y, D’Souza-Schorey C. Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol. 2005;25:389–402.
48. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37:2317–28.
49. Penault-Llorca F, Abrial C, Roelffs L, Chollot P, Cayre A, Mouret-Reynier MA, et al. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist. 2008;13:1235–45.
50. Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21:341–52.
51. Williams ED, Gao D, Redfern A, Thompson EW. Controversies around epithelial-mesenchymal plasticity in cancer metastasis. Nat Rev Cancer. 2019;19:716–32.
52. Kumar A, Bhanja A, Bhattacharyya J, Jaganathan BG. Multiple roles of CD90 in cancer. Tumour Biol. 2016;37:11611–22.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.